Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-04-21

Clinical Trial Update: The Effect of RNS60 on ALS Biomarkers [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the effect of RNS60 on ALS biomarkers has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RNS60

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2023-04-21